The 50 mg dose showing statistically significant efficacy on two scales provides strong clinical validation; anticipate Phase 3 trial design discussions with FDA and potential partnership interest. Monitor for upcoming trial initiation and biomarker data readouts.
Price Chart
Executive Summary
Alterity Therapeutics announced new Phase 2 data for its drug ATH434 in Multiple System Atrophy (MSA), showing a statistically significant 41% relative treatment effect on the MuSyCA composite scale at 50 mg and a 53% effect on modified UMSARS I, reinforcing its disease-modifying potential ahead of planned Phase 3 trials.
Key Facts
- ATH434 showed a 41% relative treatment effect on the MuSyCA scale at 50 mg (p=0.034) and 35% at 75 mg over 52 weeks
- On modified UMSARS I, ATH434 achieved a 53% relative treatment effect at 50 mg (p=0.029)
- Placebo group worsened by +9.7 points on MuSyCA, confirming scale sensitivity
- Data presented at AAN 2026 Late Breaking Science Session
- ATH434 has FDA Fast Track and Orphan Drug designations for MSA
Financial Impact
Potential blockbuster value in a $75M market cap company with no approved therapies for MSA
Risk Factors
- Phase 3 trial may not replicate Phase 2 results
- Regulatory hurdles for approval in absence of prior approved MSA therapies
- Dilution risk from future financing needs for pivotal trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278839 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (+0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 23, 2026 4d ago | 6-K | $2.09 | awaiting T+60 | — | $2.08 (−0.48%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 21, 2026 6d ago | 6-K | $2.39 | awaiting T+60 | — | $2.08 (−12.97%) |
Oct 19, 2026 8d ago | 6-K | $2.43 | awaiting T+60 | — | $2.08 (−14.40%) |
Oct 9, 2026 18d ago | 6-K | $3.12 | awaiting T+60 | — | $2.08 (−33.33%) |
Oct 5, 2026 22d ago | Press Release | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Oct 5, 2026 22d ago | 6-K | $3.22 | awaiting T+60 | — | $2.08 (−35.40%) |
Sep 25, 2026 4w ago | 6-K | $3.67 | awaiting T+60 | — | $2.08 (−43.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers